{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:16:27Z","timestamp":1761920187423},"reference-count":61,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.dld.2016.08.112","type":"journal-article","created":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T09:23:52Z","timestamp":1471944232000},"page":"1283-1289","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["The multidisciplinary management of gastro-oesophageal junction tumours"],"prefix":"10.1016","volume":"48","author":[{"given":"J.-L.","family":"Van Laethem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Messman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.H.","family":"Ilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.H.","family":"Allum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Haustermans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Matysiak-Budnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Schmiegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ph.","family":"Rougier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Th.","family":"Seufferlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2016.08.112_bib0005","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2006.09.7931","article-title":"Referral patterns, treatment choices and outcomes in locoregionalesophageal cancers: a population-based analysis of elderly patients","volume":"25","author":"Steyerberg","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0010","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s10120-015-0548-2","article-title":"Trends in gastric cancer incidence: a period and birth cohort analysis in a well-defined French population","volume":"19","author":"Chapelle","year":"2016","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.dld.2016.08.112_bib0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/bjs.6865","article-title":"EUROCARE working group: operative mortality after gastric cancer resection and long-term survival differences across Europe","volume":"97","author":"Lepage","year":"2010","journal-title":"British Journal of Surgery"},{"key":"10.1016\/j.dld.2016.08.112_bib0020","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1136\/gut.2010.228254","article-title":"Guidelines for the management of oesophageal and gastric cancer","volume":"60","author":"Allum","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.dld.2016.08.112_bib0025","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1053\/j.gastro.2012.04.032","article-title":"Consensus statements for management of Barrett\u2019s dysplasia and early stage esophageal adenocarcinoma, based on a Delphi process","volume":"143","author":"Bennett","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2016.08.112_bib0030","doi-asserted-by":"crossref","first-page":"vi57","DOI":"10.1093\/annonc\/mdt344","article-title":"Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Waddell","year":"2013","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0035","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.ejca.2010.01.019","article-title":"What reasons lie behind long-term survival differences for gastric cancer within Europe?","volume":"46","author":"Bouvier","year":"2010","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.dld.2016.08.112_bib0040","series-title":"WHO classification of tumours of the digestive system","article-title":"Adenocarcinoma of the oesophagogastric junction","author":"Odze","year":"2010"},{"key":"10.1016\/j.dld.2016.08.112_bib0045","series-title":"TNM classification of malignant tumours","author":"International Union against Cancer","year":"2009"},{"key":"10.1016\/j.dld.2016.08.112_bib0050","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1046\/j.1365-2168.1998.00940.x","article-title":"Classification of adenocarcinoma of the oesophago-gastric junction","volume":"85","author":"Siewert","year":"1988","journal-title":"British Journal of Surgery"},{"key":"10.1016\/j.dld.2016.08.112_bib0055","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","article-title":"HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer","volume":"18","author":"Van Cutsem","year":"2015","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.dld.2016.08.112_bib0060","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00428-013-1533-y","article-title":"Biomarkers for gastric cancer: prognostic, predictive or targets of therapy","volume":"464","author":"Dur\u00e3es","year":"2014","journal-title":"Virchows Archiv"},{"key":"10.1016\/j.dld.2016.08.112_bib0065","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mdi064","article-title":"Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab","volume":"16","author":"Tanner","year":"2015","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0070","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3892\/ol.2012.1031","article-title":"The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel","volume":"5","author":"Bar-Sela","year":"2013","journal-title":"Oncology Letters"},{"key":"10.1016\/j.dld.2016.08.112_bib0075","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/annonc\/mdt106","article-title":"Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116\/SWOG9008 clinical trial","volume":"24","author":"Gordon","year":"2013","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0080","first-page":"57","article-title":"HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value\u2014conclusions from 924 cases of two independent series","volume":"32","author":"Grabsch","year":"2010","journal-title":"Cellular Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0085","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/annonc\/mds622","article-title":"Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial","volume":"24","author":"Okines","year":"2013","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0090","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1055\/s-0031-1273201","article-title":"German S3-guideline \u201cdiagnosis and treatment of esophagogastric cancer\u201d","volume":"49","author":"Moehler","year":"2011","journal-title":"Zeitschrift fur Gastroenterologie"},{"key":"10.1016\/j.dld.2016.08.112_bib0095","first-page":"1299","article-title":"S2k guideline: gastroesophageal reflux disease guided by the German Society of Gastroenterology: AWMF register no. 021-013","volume":"52","author":"Koop","year":"2014","journal-title":"Zeitschrift fur Gastroenterologie"},{"key":"10.1016\/j.dld.2016.08.112_bib0100","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1053\/j.gastro.2012.04.032","article-title":"Consensus statements for management of Barrett\u2019s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process","volume":"143","author":"Bennett","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2016.08.112_bib0105","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s10120-014-0403-x","article-title":"International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus","volume":"18","author":"Moehler","year":"2015","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.dld.2016.08.112_bib0110","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/jama.2014.2511","article-title":"Radiofrequency ablation vs. endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial","volume":"311","author":"Phoa","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2016.08.112_bib0115","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.gastro.2013.11.006","article-title":"Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus","volume":"146","author":"Pech","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2016.08.112_bib0120","first-page":"113","article-title":"Early esophageal cancer in Europe: endoscopic treatment by endoscopic submucosal dissection","volume":"47","author":"Probst","year":"2015","journal-title":"Endoscopy"},{"key":"10.1016\/j.dld.2016.08.112_bib0125","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa0808145","article-title":"Radiofrequency ablation in Barrett\u2019s esophagus with dysplasia","volume":"360","author":"Shaheen","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2016.08.112_bib0130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cgh.2008.09.005","article-title":"Endoscopic submucosal dissection of early cancers, flat adenomas, and submucosal tumors in the gastrointestinal tract","volume":"7","author":"Probst","year":"2009","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2016.08.112_bib0135","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1055\/s-0032-1309403","article-title":"Endoscopic submucosal dissection in large sessile lesions of the rectosigmoid: learning curve in a European center","volume":"44","author":"Probst","year":"2012","journal-title":"Endoscopy"},{"key":"10.1016\/j.dld.2016.08.112_bib0140","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1056\/NEJMoa022343","article-title":"Extended transthoracic resection compared with limited transhiatal resection for adenocarcinomas of the esophagus","volume":"21","author":"Hulscher","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2016.08.112_bib0145","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/SLA.0b013e31815c4037","article-title":"Extended transthoracic resection compared with limited transhiatal resection for adeocarcinoma of the mid\/distal esophagus: five year survival of a randomised clinical trial","volume":"6","author":"Omloo","year":"2007","journal-title":"Annals of Surgery"},{"key":"10.1016\/j.dld.2016.08.112_bib0150","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejso.2015.09.017","article-title":"Variations among 5 European countries for curative treatment of resectable oesophageal and gastric cancer: a survey from the EURECCA Upper GI Group","volume":"42","author":"Messager","year":"2016","journal-title":"European Journal of Surgical Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0155","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2482-11-2","article-title":"Traditional invasive vs minimally invasive esophagectomy: a multicentre randomised trial (TIME-trial)","volume":"1","author":"Biere","year":"2011","journal-title":"BMC Surgery"},{"key":"10.1016\/j.dld.2016.08.112_bib0160","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/bjs.8931","article-title":"Effects of hybrid minimally invasive oesophagectomy on major postoperative pulmonary complications","volume":"99","author":"Briez","year":"2012","journal-title":"British Journal of Surgery"},{"key":"10.1016\/j.dld.2016.08.112_bib0165","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","article-title":"Survival after neoadjuvant chemotherapy or chemoradiationfor resectable oesophageal carcinoma: an updated meta-analysis Group","volume":"12","author":"Sjoquist","year":"2011","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0170","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/j.ejca.2012.07.029","article-title":"Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer\u2014differential treatment strategies for subtypes of early gastroesophageal cancer","volume":"48","author":"Lutz","year":"2012","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.dld.2016.08.112_bib0175","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2016.08.112_bib0180","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0185","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1200\/JCO.2009.22.2083","article-title":"Long term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer","volume":"27","author":"Allum Stenning","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0190","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2016.08.112_bib0195","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0200","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.4002","article-title":"Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma\/results from the UK medical Research council randomised OEO5 trial","volume":"33","author":"Alderson","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0205","article-title":"Peri-operative chemotherapy +\/\u2212 bevacizumab for resectable gastro-oesophageal adenocarcinoma: results from the UK Medical Research Council randomised ST03 trial","author":"Cunningham","year":"2015","journal-title":"ESMO-ECCO"},{"key":"10.1016\/j.dld.2016.08.112_bib0210","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1470-2045(07)70244-9","article-title":"PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial","volume":"8","author":"Lordick","year":"2007","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0215","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S1470-2045(07)70251-6","article-title":"PET-guided induction chemotherapy","volume":"8","author":"Downey","year":"2007","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0220","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-3-642-31629-6_14","article-title":"Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography","volume":"196","author":"Lordick","year":"2012","journal-title":"Recent Results in Cancer Research"},{"key":"10.1016\/j.dld.2016.08.112_bib0225","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.2010.534","article-title":"Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis","volume":"303","author":"Paoletti","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2016.08.112_bib0230","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1634\/theoncologist.2013-0178","article-title":"Management of localized esophageal cancer in the older patients","volume":"19","author":"Won","year":"2014","journal-title":"The Oncologist"},{"key":"10.1016\/j.dld.2016.08.112_bib0235","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Al Batran","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0240","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/JCO.1997.15.1.261","article-title":"Randomized trial comparing epirubicin,cisplatin and fluorouracil vs fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer","volume":"15","author":"Webb","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0245","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatinplus fluorouracil compared with cisplatin and fluorouracil as first line therapy for advance gastric cancer: a report of the V-325 study group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0250","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatine for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2016.08.112_bib0255","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or GEJ cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"The Lancet"},{"key":"10.1016\/j.dld.2016.08.112_bib0260","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1200\/JCO.2013.54.1011","article-title":"Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma","volume":"32","author":"Guimbaud","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0265","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"The Lancet"},{"key":"10.1016\/j.dld.2016.08.112_bib0270","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0275","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double blind, placebo-controlled phase III trial of apatinib in patients with chemo-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0280","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1586\/14737140.2015.1071669","article-title":"Biomarkers and novel agents in esophago-gastric cancer: are we making progress","volume":"15","author":"Dahle-Smith","year":"2015","journal-title":"Expert Review of Anticancer Therapy"},{"key":"10.1016\/j.dld.2016.08.112_bib0285","doi-asserted-by":"crossref","unstructured":"Cancer genome Atlas Research Network: comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202\u20139.","DOI":"10.1038\/nature13480"},{"key":"10.1016\/j.dld.2016.08.112_bib0290","first-page":"C081","article-title":"MIRO trial","author":"Gronnier","year":"2015","journal-title":"JFHOD"},{"issue":"5","key":"10.1016\/j.dld.2016.08.112_bib0295","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/SLA.0000000000001470","article-title":"Laparoscopic gastric mobilization reduces postoperative mortality after esophageal cancer surgery: a French Nationwide Study","volume":"262","author":"Messager","year":"2015","journal-title":"Annals of Surgery"},{"issue":"Suppl","key":"10.1016\/j.dld.2016.08.112_bib0300","article-title":"A multicentre randomized phase III trial of neoadjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: first results from the CRITICS study","author":"Verheij","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2016.08.112_bib0305","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncology"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865816306892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865816306892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T22:16:34Z","timestamp":1657145794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865816306892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1590865816306892"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2016.08.112","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The multidisciplinary management of gastro-oesophageal junction tumours","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2016.08.112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}